Xbrane Narrows Focus on Biosimilar Push as Q1 Loss Widens but Funding Outlook Improves

The latest update is out from Xbrane Biopharma AB ( (SE:XBRANE) ).

Xbrane Biopharma reported first-quarter 2026 revenue of SEK 17.3 million, sharply down from a year earlier as licensing income declined, and posted an EBITDA loss of SEK 7.8 million and a net loss of SEK 13.1 million. Ximluci product sales generated most of the revenue, R&D spending fell but still accounted for more than half of operating costs, and the company ended the period with SEK 66.7 million in cash and a significantly stronger equity ratio.

Operationally, Xbrane resubmitted or prepared to resubmit its Biologics License Application to the U.S. FDA for its ranibizumab biosimilar, with a six-month review expected and a targeted FDA decision on Ximluci in November 2026. The group also advanced development of its Xdivane biosimilar candidate on schedule and struck revised financing arrangements with partner Intas that shift certain development and CMC costs to the partner in exchange for adjusted future profit-sharing, supporting management’s view that current resources can fund operations for the foreseeable future despite increasing market competition.

More about Xbrane Biopharma AB

Xbrane Biopharma AB is a Swedish biotechnology company focused on developing and commercializing biosimilars, with a portfolio that includes ophthalmology drug Ximluci, a ranibizumab biosimilar to Lucentis. The company targets global markets, particularly Europe and the U.S., aiming to offer cost-effective alternatives to biologic therapies as patent expiries and regulatory support fuel biosimilar demand.

Average Trading Volume: 62,502

Technical Sentiment Signal: Sell

Current Market Cap: SEK226.7M

Learn more about XBRANE stock on TipRanks’ Stock Analysis page.